Natural history of chronic hepatitis C - PubMed (original) (raw)
Review
. 2002 Nov;36(5 Suppl 1):S35-46.
doi: 10.1053/jhep.2002.36806.
Affiliations
- PMID: 12407575
- DOI: 10.1053/jhep.2002.36806
Review
Natural history of chronic hepatitis C
Leonard B Seeff. Hepatology. 2002 Nov.
Abstract
Much controversy surrounds the issue of the natural history of hepatitis C virus (HCV) infection. Many authorities view the disease as inexorably progressive with a high probability of advancing over time to cirrhosis and occasionally hepatocellular carcinoma (HCC) and, therefore, likely to be responsible for causing death. Others regard chronic hepatitis C as having a variable outcome, the majority of infected persons not dying from the disease, but more likely from the comorbid conditions that so often accompany infection by this agent, or from more common medical conditions. Disagreements probably derive from the manner of conduct of the study and the populations studied. Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly. Thus, different outcomes have come from retrospective rather than from prospective studies, but both have concluded that at least 20% of chronically infected adults develop cirrhosis within 20 years. More recent studies that used a retrospective/prospective approach, focusing largely on young infected individuals, have produced different results. Among these young people, particularly young women, spontaneous resolution of the viral infection is more common than previously thought and cirrhosis has been identified in 5% or fewer of them. The major failing for all groups studied, young and old, is that natural history studies have rarely exceeded the first 2 decades, so that outcome beyond this time is not known, other than through modeling. Several host-related and extraneous factors probably affect the natural history.
Similar articles
- Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
Leone N, Rizzetto M. Leone N, et al. Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46. Minerva Gastroenterol Dietol. 2005. PMID: 15756144 English, Italian. - [Hepatitis B and C: natural course of disease].
Vince A. Vince A. Acta Med Croatica. 2005;59(5):389-92. Acta Med Croatica. 2005. PMID: 16381232 Croatian. - Projecting future complications of chronic hepatitis C in the United States.
Davis GL, Albright JE, Cook SF, Rosenberg DM. Davis GL, et al. Liver Transpl. 2003 Apr;9(4):331-8. doi: 10.1053/jlts.2003.50073. Liver Transpl. 2003. PMID: 12682882 - [Natural history of hepatitis C virus infection in dialysis].
Fabrizi F, Martin P, Lunghi G, Ponticelli C. Fabrizi F, et al. G Ital Nefrol. 2003 Sep-Oct;20(5):470-7. G Ital Nefrol. 2003. PMID: 14634962 Review. Italian. - [Risk factors for the progression of chronic hepatitis C virus infection].
Valladares Alvarez G. Valladares Alvarez G. Rev Gastroenterol Peru. 2003 Apr-Jun;23(2):126-33. Rev Gastroenterol Peru. 2003. PMID: 12853989 Review. Spanish.
Cited by
- Acute hepatitis C: to treat or not to treat.
Samala NR, Ghany MG. Samala NR, et al. Lancet Infect Dis. 2013 Jun;13(6):467-8. doi: 10.1016/S1473-3099(13)70075-6. Epub 2013 Mar 22. Lancet Infect Dis. 2013. PMID: 23523673 Free PMC article. No abstract available. - MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium. Thabet K, et al. Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757. Nat Commun. 2016. PMID: 27630043 Free PMC article. - The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries.
Vietri J, Prajapati G, El Khoury AC. Vietri J, et al. BMC Gastroenterol. 2013 Jan 17;13:16. doi: 10.1186/1471-230X-13-16. BMC Gastroenterol. 2013. PMID: 23324473 Free PMC article. - Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.
Puri CP. Puri CP. J Clin Exp Hepatol. 2011 Jun;1(1):27-33. doi: 10.1016/S0973-6883(11)60115-1. Epub 2011 Aug 26. J Clin Exp Hepatol. 2011. PMID: 25755307 Free PMC article. - Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.
Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Jazwinski AB, et al. J Viral Hepat. 2012 Apr;19(4):278-82. doi: 10.1111/j.1365-2893.2011.01546.x. Epub 2011 Nov 24. J Viral Hepat. 2012. PMID: 22404726 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources